Rhumbline Advisers raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 1.1% in the fourth ...

State of New Jersey Common Pension Fund D cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 3.1% during the 4th quarter, according to its most recent disclosure with the SEC.

Harmony Biosciences is facing more of a nightmare than sweet dreams on the road to securing a new use for its excessive ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the ...

Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a ...

Avadel Pharmaceuticals' stock is undervalued due to peak sales potential, along with the possibility of a buyout. Click here ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Harmony Biosciences currently markets pitolisant as WAKIX® in the U.S. for the treatment of EDS or cataplexy in adult patients with narcolepsy and for EDS in pediatric patients 6 years of age and ...

Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...